Date: 2015-03-24
Type of information: Licensing agreement
Compound: undisclosed discovery biologics research program focused on modulating the innate immune system
Company: BMS (USA - NY) Novo Nordisk (Denmark)
Therapeutic area: Autoimmune diseases
Type agreement: licensing
Action mechanism:
Disease: autoimmune diseases
Details: * On March 24, 2015, BMS announced the company has signed an agreement with Novo Nordisk under which BMS will acquire an exclusive global license to a discovery biologics research program focused on modulating the innate immune system as a therapy for autoimmune diseases. Terms of the agreement were not disclosed. The agreement supports Bristol-Myers Squibb’s long-standing commitment to immunoscience, a core therapeutic area with multiple innovative drug candidates in development to target immune-mediated diseases with high unmet medical needs. The innate immune system is the body’s first line of defense against pathogens and responds to exogenous agents in an antigen non-specific way to stimulate an immediate protective response. Dysregulated innate immunity plays a critical role in the induction and pathogenesis of autoimmune diseases.
Financial terms: undisclosed
Latest news:
